Skip to main content
. 2014 Oct 28;5(23):12371–12382. doi: 10.18632/oncotarget.2642

Figure 4. MELK inhibitor OTS167 exhibits anti-leukemia activity in AML cell lines.

Figure 4

(A) MTT assays for nine AML cell lines after 48-hour incubation with OTS167 at indicated doses. (B) Apoptosis assessed by Annexin and PI staining in MV4-11 and THP-1 cells treated with 25, 50 or 100nM of OTS167 for 72 hours (the numbers represent the percentage of cells in each quarter). (C) Western blot showing cleaved caspase-3 in MV4-11 cells treated with 50 and 100nM OTS167 for 48 hours. (D) Myeloid differentiation assessed by CD11b staining in U937 cells treated with 25 or 50nM of OTS167 and quantification of CD11b staining. (E) Migration of THP-1 cells treated with 100nM of OTS167 for 6 hours. (F) Cell cycle analysis performed in MV4-11 and THP-1 cells treated with 50nM of OTS167 for 24 hours, and assayed using 7-aminoactinomycin D (7AAD) and Bromodeoxyuridin (Brdu) staining.